Literature DB >> 10071245

In serous ovarian neoplasms the frequency of Ki-ras mutations correlates with their malignant potential.

C J Haas1, J Diebold, A Hirschmann, H Rohrbach, U Löhrs.   

Abstract

We analysed 44 tissue samples from serous ovarian neoplasms of different malignant potential for Ki-ras mutations by denaturing gradient gel electrophoresis (DGGE) and direct sequencing after microdissection. Point mutations at codon 12 were found in 7 of 20 tumours of low malignant potential (LMP) (35%) and in 2 of 6 well-differentiated carcinomas (33%). In contrast, no mutations were detected in the 11 poorly differentiated ovarian carcinoma samples or in the 7 serous cystadenomas. The frequency of Ki-ras mutations in serous ovarian tumours seems to correlate with the malignant potential of the neoplasms. The data favour the hypothesis of a de novo development of poorly differentiated ovarian carcinomas and do not support an evolution from LMP tumours or well-differentiated carcinomas.

Entities:  

Mesh:

Year:  1999        PMID: 10071245     DOI: 10.1007/s004280050314

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  10 in total

Review 1.  Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.

Authors:  Russell Vang; Ie-Ming Shih; Robert J Kurman
Journal:  Adv Anat Pathol       Date:  2009-09       Impact factor: 3.875

2.  Tubal origin of ovarian low-grade serous carcinoma.

Authors:  Chenglu Chen; Jie Li; Guang Yao; Setsuko K Chambers; Wenxin Zheng
Journal:  Am J Clin Exp Obstet Gynecol       Date:  2013-12-15

Review 3.  Large-scale genomic analysis of ovarian carcinomas.

Authors:  Kylie L Gorringe; Ian G Campbell
Journal:  Mol Oncol       Date:  2008-12-24       Impact factor: 6.603

Review 4.  Early events in ovarian oncogenesis.

Authors:  Dusica Cvetkovic
Journal:  Reprod Biol Endocrinol       Date:  2003-10-07       Impact factor: 5.211

5.  The molecular pathology of ovarian serous borderline tumors.

Authors:  A Malpica; K-K Wong
Journal:  Ann Oncol       Date:  2016-04       Impact factor: 32.976

6.  Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors.

Authors:  Michael S Anglesio; Jeremy M Arnold; Joshy George; Anna V Tinker; Richard Tothill; Nic Waddell; Lisa Simms; Bianca Locandro; Sian Fereday; Nadia Traficante; Peter Russell; Raghwa Sharma; Michael J Birrer; Anna deFazio; Georgia Chenevix-Trench; David D L Bowtell
Journal:  Mol Cancer Res       Date:  2008-11       Impact factor: 5.852

Review 7.  Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis.

Authors:  Jie Li; Oluwole Fadare; Li Xiang; Beihua Kong; Wenxin Zheng
Journal:  J Hematol Oncol       Date:  2012-03-09       Impact factor: 17.388

Review 8.  Recent concepts of ovarian carcinogenesis: type I and type II.

Authors:  Masafumi Koshiyama; Noriomi Matsumura; Ikuo Konishi
Journal:  Biomed Res Int       Date:  2014-04-23       Impact factor: 3.411

9.  Tubal Origin of "Ovarian" Low-Grade Serous Carcinoma: A Gene Expression Profile Study.

Authors:  Yiying Wang; Shuhui Hong; Jingyi Mu; Yue Wang; Jayanthi Lea; Beihua Kong; Wenxin Zheng
Journal:  J Oncol       Date:  2019-03-05       Impact factor: 4.375

10.  Loss of 1p36.33 Frequent in Low-Grade Serous Ovarian Cancer.

Authors:  Els Van Nieuwenhuysen; Pieter Busschaert; Annouschka Laenen; Philippe Moerman; Sileny N Han; Patrick Neven; Diether Lambrechts; Ignace Vergote
Journal:  Neoplasia       Date:  2019-05-01       Impact factor: 5.715

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.